Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845039 · ClinicalTrials.gov registry record · Phase 2
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00845039 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 4 participants.
The verdict
NCT00845039, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
Interventions
- BIOLOGICAL Cetuximab
- DRUG Irinotecan
- BIOLOGICAL IMC-A12 (cixutumumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845039
The ClinicalTrials.gov registry entry for NCT00845039 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00845039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845039 about?
NCT00845039 is a clinical study titled "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab". The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
What is the current status of trial NCT00845039?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2009-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00845039?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Irinotecan (DRUG), IMC-A12 (cixutumumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00845039?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.